Jnana Therapeutics

Edit info

Founded: 2016

Location: Boston, MA

Employee range: 50 - 200

Clinical stage: Clin1b

Therapy area: Phenylketonuria

Drug types: GEN, NPH, RAR, PED, IMM, ONC, NEU

Lead product: JNT-517

Funding: $107M C Nov 2022; $50M B Aug 2021; $50M A Dec 2017

Investors: Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures

jnanatx.com

linkedin.com

job board

Drug notes:

5+ additional undisclosed programs RD immune-mediated & inflammatory diseases, oncology, neurology

About:

Jnana Therapeutics is creating therapies to treat a wide variety of diseases by uncovering and targeting unique binding sites of highly validated protein targets. Chemoproteomics is facilitating drug discovery for previously inaccessible protein targets. Jnana has built a next-generation chemoproteomics platform, RAPID, to develop small molecule medicines for any target with unprecedented speed and efficiency. This approach is enabling Jnana to address a range of challenging target classes including SLC transporters, transcription factors and signaling scaffold proteins that are significant drivers of disease. Their lead candidate, JNT-517, is targeting a SLC transporter that plays a role in PKU.

Jobs:

Don't see a perfect job? Apply opportunistically.

Boston, Massachusetts, United States|100+ days ago

Main

Contact: recruit@workinbiotech.com